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A B S T R A C T
Recent epidemiology studies highlighted the detrimental health effects of exposure to low dose and low
dose rate ionizing radiation (IR): nuclear industry workers studies have shown increased leukaemia and
solid tumour risks following cumulative doses of <100 mSv and dose rates of <10 mGy per year;
paediatric patients studies have reported increased leukaemia and brain tumours risks after doses of
30–60 mGy from computed tomography scans. Questions arise, however, about the impact of even lower
doses and dose rates where classical epidemiological studies have limited power but where subsets
within the large cohorts are expected to have an increased risk. Further progress requires integration of
biomarkers or bioassays of individual exposure, effects and susceptibility to IR. The European DoReMi
(Low Dose Research towards Multidisciplinary Integration) consortium previously reviewed biomarkers
for potential use in IR epidemiological studies. Given the increased mechanistic understanding of
responses to low dose radiation the current review provides an update covering technical advances and
recent studies. A key issue identiﬁed is deciding which biomarkers to progress. A roadmap is provided for
biomarker development from discovery to implementation and used to summarise the current status of
proposed biomarkers for epidemiological studies. Most potential biomarkers remain at the discovery
stage and for some there is sufﬁcient evidence that further development is not warranted. One biomarker
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60 J. Hall et al. / Mutation Research 771 (2017) 59–84identiﬁed in the ﬁnal stages of development and as a priority for further research is radiation speciﬁc
mRNA transcript proﬁles.
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It is well known that exposure to IR1 increases the risk of cancer
and, at higher doses, diseases such as cardiovascular diseases and1 Abbreviations: 3H: tritium; 8-oxodG: 8-oxo-7,8-dihydro-20-deoxyguanosine; AT: Ata
and Rad3 related; BER; base excision repair; bp; base pair; CBMN: cytokinesis block micr
CT: computerized tomography; CURE: Concerted Action for an Integrated (biology-dosim
variation; CVD: cardiovascular diseases; DC: dicentric; DDR: DNA damage response; D
triphosphate; DoReMi: European project towards Low Dose Research towards Multidis
quantify risks for paediatric computerized tomography and to optimise doses; EPR: ele
association study; HO: hydroxyl radicals; HPLC–MS: Liquid chromatography–mass spe
HRS: hyper radiosensitivity; I: iodine; IR: ionizing radiation; IRR: increased radiation resi
lncRNA: long-non-coding RNA; LPS: lipopolysaccharide; MAPK: mitogen-activated prot
spectrometry; mRNA: messager RNA; mtDNA: mitochondrial DNA; NBS; Nijmegan Break
Netherlands Cohort Study; NMR: nuclear magnetic resonance; OPERRA: Open Project for
Condensed Chromosome; PTC: papillary thyroid carcinoma; Pu: plutonium; qRT-PCR:q
Dosimetry EU Coordination action; RNA: ribonucleic acid; ROS: reactive oxygen species
operating procedures; Sr: strontium; STROBE-ME: STrengthening the Reporting of OB
centromere-ﬂuorescence in situ hybridization; TL: telemore length; U: uranium; UNSCcataracts [1,2]. However, there are important unanswered ques-
tions that need addressing to increase our understanding of the
impact of low dose (below 100 mSv)/dose rate exposure (0.1
mSv min1) [3]. These include: Do tissues differ in theirxia telangiectasia; ATM: Ataxia telangiectasia mutated; ATR: Ataxia telangiectasia
onuclei; ccfDNA: Cell-free circulating DNA; CNV: copy number variant; Cs: cesium;
etry-epidemiology) Research project on Occupational Uranium; CV; coefﬁcient of
RC: DNA repair capacity; DNA: deoxyribonucleic acid; dNTP: deoxyribonucleotide
ciplinary Integration; DSB: double strand break; EPI-CT: Epidemiological study to
ctron paramagnetic resonance; FDXR: Ferredoxin Reductase; GWAS: genome-wide
ctrometry; HCR: Host cell reactivation; HRR: homologous recombinational repair;
stance; LDR: low dose rate; LET: linear energy transfer; LFS: Li-Fraumeni syndrome;
ein kinase; miRNA: micro RNA; MN-RET: Micronucleated reticulocytes; MS: mass
age Syndrome; ncRNA: non-coding RNA; NHEJ: non-homologous end joining; NLCS:
 European Radiation Research; PBL: peripheral blood lymphocytes; PCC: Premature
uantitative reverse-transcriptase PCR; RENEB: Realising the European Network of
; RT: reverse transcription; SNP: single nucleotide polymorphism; SOPs: standard
servational studies in Epidemiology–Molecular Epidemiology; TC-FISH: telomere/
EAR: United Nations Scientiﬁc Committee on Effects of Atomic Radiation.
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doses/dose rates? How does inter-individual susceptibility impact
on risks of cancer and other diseases? Are multiple exposures
separated in time additive? How does radiation quality impact on
radiosensitivity? Do internal emitters show the same dose
response as external radiation?
Recent epidemiology studies have highlighted the importance
of this research area. For instance increased risks of leukaemia and
solid tumours were seen among   300,000 nuclear industry
workers exposed to very low dose rate (typically <10 mGy per
year) and cumulative doses <100 mSv [4,5]. Increased risks of
leukaemia and brain tumours were also reported in paediatric
patients following doses of 30–50 mGy from CT scans [6,7] and an
excess risk of childhood leukaemia following bone marrow doses
of a few mGy of natural background gamma radiation [8].
Questions arise, however, about the impact of even lower doses
where the power of classical epidemiological studies is limited and
it is not currently possible to identify whether a subset of
individuals within these large cohorts have an increased risk.
Molecular epidemiology studies could increase our under-
standing of the effects of low dose/dose rate radiation exposures on
health. In 2012, potential biomarkers for use in such studies were
reviewed as part of the European DoReMi (Low Dose Research
towards Multidisciplinary Integration) project (http://www.dor-
emi-noe.net) [9]. This review of radiation biomarkers of exposure,
susceptibility, late effects and persistent effects and discussion of
logistical and ethical aspects of large studies and the relevance of
biomarkers for assessing the cellular and physiological effects of
low dose IR exposure concluded that although there are many
potential biomarkers none were sufﬁciently validated for use in
large radiation epidemiology studies.
The present review aims to update the Pernot et al. paper,
focusing on recent technical advances and studies carried out on
existing or new biomarkers after low dose exposures. Based on this
evaluation the goal is to identify those biomarkers that should be
prioritised to help epidemiology studies address the outstanding
questions of the impact of low dose/dose rate exposures.
Biomarkers for cardiovascular effects have recently been reviewed
as part of the DoReMi initiative [10] and are not covered here. This
paper assesses which biomarkers and bioassays are ready to be
used for evaluating individual radiosensitivity and enhancing our
understanding of the shape of radiation dose-response curves for
different health outcomes and are discussed in the context of
epidemiological study designs and availability of biological
samples. For the ﬁrst time, a road-map is proposed for biomarker
development for radiation epidemiology studies and the present
status of radiation biomarkers in different stages of development
and validation assessed in this context.
2. General epidemiological and biomarker considerations
The Pernot paper [9] provided a deﬁnition and classiﬁcation of
biomarkers, and summarised the characteristics of a good
biomarker which is not revisited in detail here. The choice of
biomarkers depends on the objective of the study and is also
dictated by the epidemiological study design: case-control studies
of diseases with a long latency period (such as cancer) will
generally not be able to use biomarkers of exposure as the
exposure will have occurred decades before biological sampling is
done; cohort studies in which subjects are followed-up for
decades, on the contrary, may permit biomarkers of exposure
and biomarkers of effects to be examined in the very few studies
where repeated collection of biological material from the same
individuals over time is possible. Thus the issue of the time range
over which an endpoint is persistant is essential in consideringhow informative it may be as a biomarker in epidemiological
studies.
Ideally, radiation epidemiology biomarkers should be speciﬁc
to radiation and independent of other environmental exposures
such as tobacco or other treatments. Such a biomarker would
simplify analysis and help to substantiate radiation causality.
However, biomarkers often lack speciﬁcity and may reﬂect
exposure to other environmental agents or chronic conditions
such as inﬂammation. Of course, they may still be informative in
predicting the development of radiation-induced disease if such
exposures are, for example, additive or interactive. Such biomark-
ers could be useful provided information on potential modifying/
confounding factors can be collected in the epidemiological studies
to allow an assessment of interactions. All biomarkers must be
reproducible between laboratories and over time, biologically
plausible, and practical to use in large studies in terms of the study
design, cost and feasibility of sample collection and analysis and
preferably make use of biological samples collected non-invasively
(e.g. saliva, nails, hair follicles, urine).
In addition to measuring endpoints in biological samples
exposed in vivo, responses to IR can be measured by irradiating
biological samples ex vivo under deﬁned experimental conditions.
The approach has inherent limitations related to the unknown
effect of time between exposure and the collection of biological
samples being assayed. It also requires samples to be stored to
ensure that biological activities assayed ex vivo reﬂect those in vivo.
Despite these limitations ex vivo irradiations are useful in
molecular epidemiological studies where a) repeated sampling
before and during irradiation is not possible, for example to assess
DRC using the formation and persistence of gamma H2AX (gH2AX)
(see Section 3.2.2) and b) in retrospective studies where it is not
possible to measure biological responses after an exposure that
occurred many years ago.
Low dose radiation biology research has identiﬁed several
approaches as promising avenues for the development of radiation
epidemiology biomarkers (see for instance the recent commentary
from National Council on Radioprotection and Measurements
[11]). Moving from a biomarker discovery stage to validation and
application in a molecular epidemiological setting requires
biospecimen focused research to identify possible pre-analytical
variables (e.g. processing delay, storage conditions, storage time,
freeze/thaw cycles) that might affect biomarker detection and
sufﬁciently large numbers of suitable biological samples for
biomarker validation. Indeed, there remains a need to increase
the number and size of radiation epidemiology biorepositories and
to identify populations where sampling is feasible and potentially
informative. For instance, studies investigating occupational
exposures might be particularly amenable for the collection of
multiple biological samples for assay comparisons, as samples can
be collected during routine medical surveillance, subject to
appropriate ethics clearance and agreements [12,13]. In parallel
with the collection of biological samples, collecting “metadata”
(e.g., radiation dose and information on other factors which may
inﬂuence biomarker results, such as age, sex, socioeconomic status,
body mass index, and medication use) is essential for interpreting
biomarker results. It can, therefore, be efﬁcient to collect biological
samples in subsets of cohorts for which a substantial amount of
metadata is available, such as in the occupational setting [14,15] or
in the medical therapeutic setting (see for example [16]) where
data and samples can be obtained before, during and after
treatment as part of routine clinical patient follow-up.
In radiation epidemiology, there is interest in biomarkers
involving biological samples that do not require drawing blood. For
instance saliva has potential as a biological sample for biomarker
development and in particular biomarkers of exposure [17]. Such
an approach is particularly attractive when a large number of
62 J. Hall et al. / Mutation Research 771 (2017) 59–84samples are required. Finger/toe nails are also easy and cheap
biological samples to obtain. Hogervorst et al. [18] reported their
comparison of DNA isolated from toenail samples stored for
>25 years from the Netherlands Cohort Study [19] versus other
sources of DNA. Although nail DNA was considerably degraded, it
could be genotyped for a limited set of SNPs. For genotyping using
next generation sequencing where DNA degradation is less of an
issue, nails may therefore be an attractive DNA source.
Pilot studies and the subsequent validation of biomarkers
require access to suitable biospecimens. These may be unavailable
in existing biobanks and require assessing the suitability of
alternative biospecimens or collecting new samples. For instance, a
recent proof-of-principle study showed that volatile organic
compounds in exhaled breath could be used to estimate radiation
exposure [20]. However as discussed below, validating such
measurements for integration into molecular epidemiological
studies requires further work to assess the feasibility of the
approach and, as appropriate samples are not already biobanked,
sample collection. For other studies of potential biomarkers it
might be possible to use stored samples, but the SOPs used for the
collection and processing of materials may not be suitable for all
applications. The development and validation of SOPs increase
reproducibility and are essential steps in collecting and exploiting
biological samples. This is particularly the case in multicenter
studies, where protocol variations often considered fairly mun-
dane, such as methods for assessing DNA yield, can differ
substantially and inﬂuence results [18]. Recent publications have
explored approaches for improving biomarker reproducibility by
identifying sources of variability and highlighting the importance
of biospecimen focused research to optimise SOPs. For example it
has been shown that processing delays and the number of freeze/
thaw cycles affects miRNA expression levels [21]; miRNA expres-
sion levels are also affected by the method used for their isolation
and the platform used for analysis [22] and the choice of primer
pairs for the qPCR assessment of mRNA transcript levels, which
need to reﬂect alternative splicing, can signiﬁcantly impact on
results [23]. Clearly such considerations will impact on cost and a
careful cost/beneﬁt evaluation is needed to justify the use of any
biomarker in a molecular epidemiology setting and any changes in
operating procedures.
Molecular epidemiology poses special ethical issues that were
discussed by Pernot et al. [9] and, in more detail, by Gallo et al., who
discussed the need for strengthening the reporting of molecular
epidemiological studies and outlined the STROBE-ME recommen-
dations [24]. Advances in laboratory techniques enable the
extraction of DNA, RNA and proteins from many stored samples
at a sufﬁcient quality and quantity for use in many -omic
approaches, opening up the possibility to investigate biobanked
samples for endpoints that were not included in the original
informed consent forms. This is particularly the case for genetic
analyses where, due to technical improvements and reductions in
costs, sequencing of whole genomes is feasible in large cohorts.
Currently most studies do not give information on individual
health risks to study participants. Indeed few biomarkers have
been validated in prospective studies as being predictive for the
likelihood of developing a disease. In coming years these issues
will evolve as the understanding of risks associated with individual
susceptibility, and the speciﬁcity and sensitivity of different
endpoints to assess individual risk, become clearer.
3. Potential IR biomarkers
In this update we consider progress in IR biomarker develop-
ment and validation in molecular epidemiology settings using the
classiﬁcations of the Pernot et al. review [9] and, as in this review,
due to the nature and biokinetics of the dose distribution,approaches for the biological estimation of dose for internal
emitters have been considered separately.
3.1. Cytogenetic biomarkers
3.1.1. Cytogenetics biomarkers of low dose exposure
The DC assay remains the international biodosimetry “gold
standard” for recent radiation exposures [25] and is the technique
with which newer biodosimetric approaches are compared. The DC
assay can detect exposure to 0.1 Gy if up to 1000 cells are analysed
and, based on the distortion of the Poisson distribution of the
number of aberrations/cell, differentiates between partial and
whole body exposures or to high or low LET radiation [26]. The
scoring of DC based on chromosomal morphology requires a high
level of expertise, and time to analyse large numbers of cells.
Automated DC scoring systems have been developed (see for
instance [27–31]) and international networks have attempted to
harmonize manual and automated scoring approaches [32–37].
However, automated DC scoring detects only half of the giemsa-
stained dicentrics and rejects many metaphases. DC scoring can be
simpliﬁed with the application of TC-FISH, which simultaneously
stains telomeres and centromeres. This technique allows the
detection of certain conﬁgurations of dicentrics which is techni-
cally challenging with classical Giesma staining and allows
increases after doses >100 mGy to be assessed by counting 1000
cells [38]. The impact of lower doses can be assessed by counting
more cells (see Table 1).
The DC assay has a low background, a high comparability
between the in vivo and in vitro dose response and a low inter-
individual variability. It should, therefore, be able to assess age-
related sensitivity. Technical advances permiting high through-put
analysis [31] should allow investigations into the low dose CT
exposures. The latter has been hampered, for example, by the high
number of cells required to resolve a 1.5–2 fold increase in IR
induced dicentrics in umbilical cord blood [39,40] and children
under 5 years of age (Gomolka et al. unpublished data) compared
to levels seen in blood from adults after high dose exposures.
The well-established and standardized CBMN assay in PBLs
remains a signiﬁcant biodosimetry tool for IR exposure and a
potential alternative to the DC assay, as it requires less time for
evaluation of the results and cytogenetic expertise [25,41,42]. It too
can be improved using centromeric probes and used for
retrospective dosimetry [43]. Nevertheless, it does not achieve
the sensitivity and speciﬁcity of the DC assay.
MN-RET is also recognised as a sensitive biomarker of
cytogenetic damage [44] that can be measured using ﬁxed
peripheral blood samples. The MN-RET assay shows a linear dose
response (R2 0.988) after X-rays and also internal exposure
following the injection of the radioisotope 18F FDG (R2 0.999) in
the mouse [45]. This increase was signiﬁcant at 25 mGy after X-ray
whole body exposure and at 33 mGy after 18F FDG exposure,
demonstrating for the ﬁrst time that the induction of DNA damage
to mouse bone marrow can be detected and quantiﬁed accurately
following injection of 18F FDG.
The MN-RET assay has not been extensively assessed in humans
[46,47]. Issues such as inter-individual variability with larger study
numbers and identifying confounding factors, such as diet [48] and
alcohol intake [49] need to be resolved to assess its use as a
biomarker of exposure. Nevertheless, the approach is worth
further investigation because it can assess levels of genetic damage
in the bone marrow, a critical organ for leukaemia, following acute
or chronic low dose external exposure or following internal
contamination.
In summary, the DC assay remains the best biodosimetry
biomarker even if less labour intensive methods such as CBMN and
MN-RET show promise. One outstanding question to be resolved is
Table 1
Summary table of cytogenetic biomarkers.
Exposure Assessment Lower
dose
limit
Speciﬁc for
Radiation
quality
Partial
Body
exposure
Individual
radio-
sensitivity
Age dependent
radiosensitivity
in low dose
range
Labor
intensive
Automation possible Applicable
for large
scale
studies
Past Current
Dicentrics No Yes 50 mGya Yes Yes Nob Yes Yes if not
automated
Yes (described for Giemsa
stained dicentrics or by
using PC and TC ﬂuorescent
probes)
Yes
Translocations Yes (at
group
level)
Yes 300 mGy Yes Yes No** No Yes No Yes
Intra-
chromosomal aberrations
Yes Yes 150 mGy Yes No No No Yes No Yes
Micronuclei Yes (only
group
level)
Yes Several
tens of
mSv
No No No No No Yes Yes
MN-RET Possibly
(chronic
genetic
instability)
Yes
Time
dependent
10 mGy Works after
external and/
or internal
exposure
Bone
marrow
has to be
exposed
Not tested Not tested No Yes Yes
Telomere
length
No No Not
assessed
No Not
assessed
Possibly Probably No Not
assessed
Yes Yes
a Requires the evaluation of 10,000 cells to evaluate exposures to 50 mGy.
b Radiation sensitive syndromes such as ATM and NBS homozygote carriers do show increased levels.
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bioassays such as gH2AX, micronuclei and clonal survival assay
(see for instance [50–52]) and changes in chromosomal aberration
types [39,40] have been explored but lack the sensitivity in the low
dose range. Automation of the DC assay offers the possibility to
assess effects at doses <100 mGy if up to 10,000 cells are analysed.
This is, however, not an appropriate method for the assessment of
past exposures and other methods such as the detection of stable
translocations or micronuclei should be used.
3.1.2. Cytogenetic biomarkers of susceptibility and late effects
Cytogenetic endpoints (e.g. the G2 assay) are also of interest as
biomarkers of susceptibility and late effects. Several groups
showed increased chromosomal radiosensitivity in cancer patients
in comparison with matched healthy controls. Chromosomal
radiosensitivity is clearly an inherited phenotype demonstrated
in several family and twin studies (reviewed in [53]). However,
cancer patients radiosensitive in one cytogenetic assay were not
necessarily radiosensitive in a different assay [54]. Also, studies of
cytogenetic tests of cancer susceptibility did not investigate
radiation speciﬁcity. Progess has been made in identifying genetic
variants associated with cancer predisposition, which might be a
better approach (see Section 3.3). Regarding use of cytogenetic
assays as biomarkers of late effects, studies showed some potential
to predict risk of radiotherapy side-effects but, in general, the
results are equivocal.
3.1.3. Cytogenic biomarkers of persistent effects
Translocation frequency, as detected by the monochrome FISH
technique, was found to be linearly related to individual red bone
marrow dose from incorporated Sr-89/90 above 300 mGy
>50 years after irradiation in the Techa River residents [55]. The
FISH translocation assay is also informative for combined external
gamma and internal doses from Sr-90, albeit with fairly large
uncertainties [56]. A signiﬁcant linear relationship between
translocations and red bone marrow dose >300 mGy from past
prolonged external gamma-radiation exposure was also found in
studies of Mayak workers [57]. However establishment of the
relationship between translocations and dose from internal alpha-
particle exposure is more complicated since translocations may be
part of complex aberrations with more than three differentchromosomes involved, again at moderate to high doses [58–60].
Studies of Mayak workers also demonstrated an association
between intra-chromosome aberration frequency and absorbed
dose from internal alpha-particles in RBM [61–63]. Estimation of
individual dose using these approaches has a substantial
uncertainty (90–100%), however the uncertainty for group dose
estimates is lower (30–40%). Thus individual retrospective dose
assessment is highly problematic [64].
The modiﬁed micronucleus-centromere test has also been used
as an exposure biomarker [12]. In former uranium miners with
high absorbed dose from Rn and its progeny to the lung, an increase
was found in the number of centromere-free micronuclei (micro-
nuclei containing only acentric fragments), but not in the overall
frequency of micronucleus containing cells in peripheral blood
lymphocytes, over a decade after the end of employment when
compared to an unexposed control group [12]. Results of this study
are in agreement with other studies of former uranium miners
from Germany [65], suggesting that cytogenetic damage from
alpha-radiation can persist for many years after exposure.
3.1.4. Telomere length and loss as biomarkers of susceptibility and
exposure
TL varies between individuals [66] and decreases with age. Cells
with short or damaged telomeres have increased genetic
instability, which probably plays an important role in cancer
etiology. Individuals with short versus long telomeres also have
more radiation induced micronuclei [67]. Indeed, a strong
correlation between TL and clinical radiosensitivity was demon-
strated in many in vitro and in vivo studies (reviewed in [68]). For
example a recent study found that while mean TL was not affected
in peripheral leukocytes from 25 patients after radiation treatment
(mean dose 52 Gy), there was a signiﬁcant decrease in the
proportion of cells with short telomeres [69]. Comparisons of TL
in Hodgkin lymphoma survivors with and without cardiovascular
disease indicated that survivors who develop cardiovascular
disease post-radiotherapy have signiﬁcant telomere shortening
[70]. Thus, whilst TL, telomere maintenance, and telomere
dysfunction may play a role in the prediction of individual
radiosensitivity and in the long-term health risks following high
dose IR exposure, studies need to examine the variation after low
dose exposures and to identify all confounding factors.
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thyroid tumour tissue
Chromosomal rearrangements are common genetic alterations
in PTC, the most common thyroid tumour. These include
rearrangements involving the RET proto-oncogene, the so-called
RET/PTC rearrangements, all of which lead to constitutive
activation of the MAPK pathway. The frequency of the RET/PTC1
and RET/PTC3 rearrangements was initially associated with
radiation exposure levels in a study of the atomic bomb survivors
and some, but not all, studies of post-Chernobyl PTC [71,72].
However, similar frequencies of RET rearrangements have been
observed in PTC without any history of radiation exposure [73] and
RET/PTC3 rearrangements in radiation induced and sporadic PTCs
from young patients, indicating a relation with age of PTC onset
rather than with radiation exposure history [74–76].
Ricarte-Filho et al. reported a higher frequency of fusion
oncogenes in post-Chernobyl radiation-induced PTCs (84.6%)
compared to sporadic PTCs (33.3%) in young people from the
Ukraine. These included rare TRK and BRAF rearrangements and
two newly described fusion oncogenes ETV6-NTRK3 and AGK-
BRAF [77]. However, these differences should be interpreted with
caution as whilst the radiation-induced PTCs were examined using
candidate gene assays and next-generation RNA sequencing, the
sporadic PTCs in this study were only screened for known genetic
alterations and not analysed by next-generation RNA sequencing.
As discussed by Santoro and Carlomagno [78], the study by Ricarte-
Filho and colleagues demonstrates that radiation exposure caused
a selective increase of oncogenic driver events generated by gene
rearrangements compared with point mutations. Leeman-Neill
et al., [79] detected the ETV6/NTRK3 rearrangement in 14.5% of
post-Chernobyl PTCs and 2% of sporadic PTCs from the general U.S.
population. Moreover, they showed that ETV6/NTRK3 can be
directly induced in thyroid cells in vitro after exposure to 1 Gy of
131I or gamma-irradiation and thus may represent a novel
mechanism of radiation-induced carcinogenesis. However, these
results should also be interpreted with caution as the sporadic and
post-Chernobyl PTCs were not matched. Such ﬁndings require
further validation in independent tumour cohorts including
appropriate matched PTCs from exposed and non-exposed
patients. It should be noted that chromosomal copy number
changes are also noted in thyroid tumours (see Section 3.8) and
that currently no radiation speciﬁc chromosomal signature has
been described in other tumour tissues.
3.2. DNA and nucleotide pool damage biomarkers
IR can induce DNA lesions, which are potential biomarkers of
exposure, directly or indirectly. For in-depth reviews on the
possibility of identifying radiation speciﬁc lesions, the reader is
referred to excellent recent publications [80,81]. Of the lesions
produced, DNA strand breaks can be measured directly or by using
surrogate endpoints such as gH2AX foci or assays such as the
comet assay. These techniques and their use were reviewed in
Pernot et al. [9] and only gH2AX is revisited here, since its
measurement has been integrated into several molecular epide-
miological studies (see Section 3.2.2). The nucleotide pool is also a
target of IR and indirectly of oxidative stress and recent progress on
the use of 8-oxo-dG as a biomarker of individual sensitivity to
radiation is discussed in Section 3.2.3.
3.2.1. DNA lesions
The measurement of radiation-induced DNA lesions remains a
challenge as (1) the yield of formation per dose unit is very low,
with <1 modiﬁcation per 1–10 million normal bases per gray; and
(2) many of the lesions produced by IR directly or indirectly are
similar to those generated by endogenous stress. Thus, as discussedby Ravanat et al. [80], even in the absence of radiation, oxidative
DNA lesions, such as 8-oxo-dG are detected in cells at levels around
one modiﬁcation per million DNA bases. Based on this, exposure to
about 40–50 Gy is needed to double the yield of 8-oxo-dG above
the background level. Thus, variation in levels of DNA lesions
identical to those produced by endogenous oxidative stress after
exposures to low doses may be difﬁcult to interpret in terms of
radiation exposure biomarkers. Future attention needs to focus on
lesions that are predominantly produced by IR, and not, or at a
lower level, by endogenous oxidative stress such as DNA lesions
characteristic of densely ionizing events, such as micronuclei, DC
and translocations.
In this context, recent data suggest that the decomposition of
the initially produced radicals contributes to the generation of
complex DNA lesions. One example is the cytosine adduct dCyd341
[80] and 20,30-dideoxynucleosides may represent potential bio-
markers of low energy electrons [82]. However technical progress
and conﬁrmation that such adducts are formed in vivo is still
needed before investigation in a molecular epidemiology setting.
In contrast to endogenous oxidative stress, some radiation-
induced lesions are generated in clusters. The proﬁle of lesion
clustering varies with radiation quality: high LET IR produces
greater lesion clustering due to the conﬁned energy deposition
[83]. Within this conﬁned space, direct ionisations along the DNA
backbone will generate DSBs that can be only 10–20 bp apart and
reactive free radicals leading to strand cross linking. The detection
and quantiﬁcation of clustered lesions because of their very nature
remains technically challenging but particularly interesting
because the approach has the potential to be radiation speciﬁc.
The relative proximity of different lesions in clusters generates
a challenging situation for the cellular DNA repair machinery with
the repair of clustered lesions occurring with a slower time course
compared to that of discrete DSBs and isolated lesions (see [83] for
recent review). The formation and repair of complex lesions could
have particularly marked consequences after low dose chronic
exposures and could contribute to the non-linear patterns
observed in cell survival at doses <1 Gy (see [83] for recent
review). It is technically feasible to envisage a bioassay where, for
instance, lymphocytes could be irradiated ex vivo with radiation of
different qualities and the formation of clustered lesions followed
with time using surrogate endpoints such as formation of DNA
repair foci detected by immunological based techniques or the
Comet assay. However, such bioassays require access to appropri-
ate radiation platforms and would be limited by all the technical
and sensitivity constraints that apply to such measurements.
3.2.2. gH2AX and DNA repair foci
DNA DSBs are signalled by the accumulation of phosphorylated
proteins at the damage sites forming DNA repair foci. One
prominent protein in this DDR is the histone H2AX which is
phosphorylated on Ser-139 [84], generating gH2AX that can be
detected and quantiﬁed using speciﬁc antibodies. gH2AX can also
arise in the absence of radiation exposure following replication
fork stalling/collapse at regions of single stranded DNA and other
processes that directly or secondarily induce DSBs such as the
repair of lesions including DNA adducts, crosslinks, and UV-
induced photolesions [85]. However the staining patterns are often
morphologically different from the punctuate staining observed
after DSB induction (see [86] for review) and with appropriate care,
for example by using non-replicating lymphocytes, the gH2AX
signal can speciﬁcally monitor DSBs.
The formation and persistence of gH2AX with time after
radiation exposure has the potential to be a sensitive biomarker of
exposure. Indeed foci can be detected after radiation exposure to
low doses (10 mGy) such as those received after a CT scan
[52,87,88]. However, detailed evaluation of gH2AX as a biomarker
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are discussed below. A further, important limitation is that the
gH2AX signal disappears rapidly after exposure. Nonetheless,
gH2AX can be used as a biomarker of DRC and thus as a potential
biomarker of susceptibility.
3.2.2.1. Assay design and validation. A number of methodological
and technical issues relating to the measurement and comparison
of gH2AX in human populations have been highlighted in a recent
systematic literature review of 68 studies, published between 2005
and 2012, that reported gH2AX levels as biomarkers of either DNA
damage or repair [86]. The sample size in most of the studies was
generally low (mean number 38 ranging from 5 to 352) with only
7/68 having a study group of 100 or more individuals. Comparing
the different systems to assess and quantify gH2AX foci numbers
or ﬂuorescence (automated microscopic analysis, FACS analysis,
laser scanning cytometer), FACS based methods are emerging as a
fast, reliable method to analyse a large number of cells, increasing
the strength of the statistical analysis. In addition, they allow
assessment of heterogeneous populations and discrimination of
cells in different phases of the cell cycle. However, compared to
microscopic analysis, the quantiﬁcation of both the number and
size of foci/cell is not possible. Considerable technical variability
has been observed between techniques. FACS analyses showed that
the standard error of the mean often reached more than 20% [89]
and, using a laser scanning cytometer to quantitatively total
ﬂuorescence per cell from triplicate slides, the average CV was
estimated to be 8.28% and 9.69% for endogenous and radiation
induced g-H2AX levels, respectively [89]. Data from automated
microscopic analysis indicated a CV of <7.5% following radiation
(1 Gy X-ray) while for endogenous damage it was 20% (Gomolka
personal communication).
As discussed by Valdiglesias et al. [86] a critical measure for
assay standardisation and an important consideration to allow the
comparison of results between centres, is the availability of an
expected range of reference values to validate protocols and
scoring criteria. Whilst numbers of basal gH2AX foci detected in
peripheral blood by microscopy have been documented, no
reference values could be reported in studies using ﬂow cytometry
which could limit inter-laboratory comparisons. In addition, the
number of events analysed differ largely depending on the
methodology used, which in turn will impact on the statistical
analysis and the quantitative comparisons between studies.
Another factor that impacts on basal gH2AX foci levels is the
cell type. Indeed, whilst the gH2AX assay can be applied to most
types of cell or tissue, differences in background levels are
reported. The choice of tissues will also depend on the purpose of
the study and what is feasible and ethical to collect from the study
population. The method of blood collection and treatment of
samples, as well as the factors discussed above relating to
technique and protocols, impact on gH2AX quantiﬁcation and
can explain part of the variation seen between laboratories in
gH2AX measurements [88,90,91]
3.2.2.2. Intra-and inter-individual variation in response. There is
limited published information on intra-individual variability in
terms of gH2AX foci levels. For example, the analysis of two
independent repeated blood samples from 8 males of gH2AX
background levels and radiation induced levels resulted in reliable
measurements with no statistically signiﬁcant differences [92].
The variability observed was about 12%, within the technical
variability for the assay.
Substantial inter-individual variability has been reported using
stimulated or non-stimulated lymphocytes [93–95], lymphoblas-
toid cell lines [16] as well as circulating lymphocytes from prostate
and breast cancer patients after fractionated radiotherapy [95](reviewed in [86,95]). Individual factors such as age, gender,
ethnicity and life style have been shown to affect the level of
endogenous gH2AX radiation induced foci and residual foci after
DSB repair [86,93,94]. For example the induction of g-H2AX at
0.5 h after ex vivo blood irradiation, and peak formation at 2 h were
independent of age, gender and ethnicity but varied with race and
alcohol use, which delayed the peak to 4 h [94].
3.2.2.3. Suitability for assessment of exposure and radiation quality
3.2.2.3.1. Suitability of the procedure. Several comparisons of
gH2AX measurements in the high dose range [34,96,97] and
one in the low dose range [88] have been performed using blood
samples irradiated ex vivo to assess this endpoint for biodosimetry
purposes. Compared to other endpoints (dicentrics, micronuclei,
gene expression), the gH2AX assay was the most rapid, providing
results within 24 h. However, it showed considerable variability at
both high and low doses (0.1–6.4 Gy), although the ﬁndings
indicated that, based on gH2AX levels in lymphocytes, the most
severely exposed individuals within a cohort could be identiﬁed,
enabling their prioritisation for accurate chromosome dosimetry
[97]. If the levels of gH2AX are to be used for biodosimetry,
calibration curves for residual damage at different time points after
exposure, adjusted for cell type and age are urgently needed (see
below). Despite these limitations, it has to be recognised that levels
of gH2AX could provide a means of triage after a radiation incident
and simple, fast and inexpensive protocols have been developed
that make use of ﬁnger-prick-sized blood volumes [98,99].
3.2.2.3.2. Suitability to estimate low dose exposures. An inter-
laboratory low dose range comparison [88] using ex vivo irradiated
lymphocytes showed that blinded samples could be successfully
ranked on the basis of exposure dose (from 10 to 100 mGy) by
monitoring mean foci/cell and that doses as low as 10 mGy
analysed 30 min post exposure could be distinguished from sham-
irradiated control samples. However, while a low level of gH2AX in
lymphocyte samples can indicate a low dose exposure, it did not
accurately reﬂect an individual’s exposure dose in the low dose
range (10–50 mGy) due to technical and inter-individual variability
as discussed above.
In contrast to exposure to a uniform acute dose, accidental
partial body irradiation to a high dose (but causing a low total body
dose) may be assessed more efﬁciently using foci analyses than by
assessing dicentric formation [95,100,101]. Among breast and
prostate cancer patients receiving radiotherapy, Zahnreich et al.,
demonstrated that foci quantitation in peripheral leukocytes
immediately after a single acute heterogeneous radiation exposure
to a small radiation ﬁeld in the body is far more sensitive to the
absorbed equivalent whole-body dose than the analysis of
unstable aberrations (dicentrics) [95].
3.2.2.3.3. Suitability for assessing radiation quality. The spatial
distribution of radiation-induced DNA lesions within the cell
nucleus depends on radiation quality. As discussed above, heavy
ions, alpha particles and also low energy (e.g. 29 kV) X-rays induce
a complex DNA damage pattern with densely localised DNA lesions
which are difﬁcult to repair accurately. Considerable progress has
been made in our understanding of the DNA repair proteins
involved in the repair of different DNA lesions by recording the
cellular and spatial distribution of different DNA repair enzyme
induced foci, the phosphorylation-dephosphorylation kinetics and
the foci size distribution with time [102–107]. Additional
information about the complexity of the DNA damage and the
inﬂuence of radiation quality can also be gained by double labelling
of proteins involved in different repair pathways, such as 53BP1
and gH2AX [106,108]. Whether such measurements can be used in
a bioassay setting, discussed below, remains to be established, but
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and possibly inter-individual variability in DRC.
3.2.2.4. gH2AX as a biomarker of susceptibility. In contrast to the
difﬁculties of exploiting gH2AX analysis for assessing exposure,
there is accumulating evidence that the persistence of gH2AX with
time after irradiation can be used as a surrogate endpoint to assess
DRC, thereby reﬂecting its use as a biomarker of susceptibility.
Indeed a deﬁciency in DNA repair, and in particular DSB repair has
been shown to correlate with radiation sensitivity in patients
diagnosed with AT, NBS, Ligase 4 syndrome (and other NHEJ
deﬁciencies), Fanconi anaemia and a number of other syndromes
(reviewed in [86,102]). Altered gH2AX foci formation and
persistence with time has also been linked to tumour radiation
sensitivity (for examples see [109]), severe acute and late radiation
toxicity (reviewed in [101,110]) and the risk of second malignant
neoplasms in childhood cancer survivors [16]. However
contradictory results on the ability of foci analyses to detect
DDR defects as a surrogate marker for genetic radiation sensitivity
exist and not all DDR defects will be resolved by one biomarker.
Radiosensitivity detected by clonogenic assays does not always
correlate with detectable defects in gH2AX removal, particularly
for the analysis of patients with hypomorphic genetic changes
[111]. This may be due to the presence of cells in different cell cycle
phases in the test material resulting in a high non DSB speciﬁc
background of gH2AX the use of inappropriate cell systems, e.g.
lymphocytes in G0 state for analysis of homologous
recombination; the challenging radiation dose, which may not
be high enough to resolve slight differences in repair efﬁciency; or
the way in which the data are statistically analysed. Usually the
mean or median number of foci remaining after a deﬁned repair
time, or time dependent repair kinetics is the endpoint assessed to
monitor DRC. A novel approach proposes that the average number
of foci based on the cell cycle distribution should be used [102]. The
co-localisation ratio of gH2AX to 53BP1 can also serve as a
parameter for radiation sensitivity. It was shown to be 1 in a
normal cell line but to deviate from this ratio in radiosensitive cell
lines. According to Martin et al. even mild differences in repair
defects, masked using standard average foci calculations, can be
distinguished using these strategies [102]. This needs validating in
further cell lines or lymphocytes with known radiation sensitive
phenotypes. Finally, the radiation exposure scheme may also be
important. It is possible that after a single acute exposure, less
inter-individual variation in DNA repair is seen than after
fractionated irradiation as used in radiotherapy protocols [112].
In summary, detailed analysis has suggested that gH2AX
analysis has limitations in its utility as a biomarker to detect low
dose exposure due to technical and inter-individual variability, by
confounding effects caused by exposures other than radiation
including disease states. However, the assay does have the
potential to be suitable for assessment of DSB repair capacity,
which is important for assessing the response to radiation
exposure.
3.2.3. Extracellular 8-oxo-dG
Extracellular 8-oxo-7,8-dihydro-20- deoxyguanosine (8-oxo-
dG) in blood serum, urine and cell culture medium has been
suggested to be a general biomarker of oxidative stress. The levels
vary with life style factors, certain disease states and exposure to
different stressors such as IR [113–115]. As previously discussed
[9], extracellular 8-oxo-dG levels in blood and urine is not a speciﬁc
biomarker of radiation exposure due to the impact of confounding
factors. However extracellular 8-oxo-dG as a biomarker for
individual sensitivity to radiation may be a more promising
application both as a diagnostic tool for personalized radiotherapy
and as tool to better understand the extent of radiation-responsevariations in the normal population. Used in a bioassay, changes in
the extracellular levels of 8-oxo-dG in blood serum in response to
ex vivo low dose radiation have been shown to correlate with acute
or late healthy tissue adverse reactions [115–119]. The develop-
ment of techniques for analysis of 8-oxo-dG in saliva is ongoing and
can add to the usefullness of saliva as a non-invasive source for
biomarker studies in radiation research [17]. Further studies are
needed to validate that 8-oxo-dG can be used as a diagnostic tool
for individual sensitivity as well as of the mechanisms linking
oxidative stress response with individual sensitivity.
3.3. Biomarkers related to germline variants
The established genetic basis for radiosensitivity underpins
research aimed at identifying germline variants as biomarkers of
susceptibility to radiation-induced health effects [120]. An
advantage of the approach is that, once identiﬁed, any test will
not suffer from the poor reproducibility associated with functional
assays measuring radiosensitivity. There is no need to assess
biomarker precision, accuracy and cross laboratory reliability as
the technology needed is available in clinical laboratories. Germ-
line variant biomarker research is all about discovery  ﬁnding
enough variants to develop a test to identify individuals who are
radiation sensitive. A disadvantage is the need for very large
collaborative studies to identify sufﬁcient variants.
Supplementary Table 3.3.1 lists the currently known genes
where rare mutations are associated with susceptibility to
radiation-induced effects. Many are associated with the DDR
and are either very likely or known to increase risk of radiation-
induced cancers. However, the rarity of homozygous carriers of
such gene mutations in the general population and the fact that
such individuals are generally identiﬁed phenotypically limits
their contribution to radiation sensitivity in population studies.
Heterozygous carriage of gene mutations associated with certain
DDR disorders can confer a subtle phenotype, including cancer
predisposition, and there is mounting evidence from mouse and
human studies that even a two-fold reduction in the levels of some
proteins can confer a signiﬁcant increase in cancer risk [121].
Indeed an increased risk of primary breast cancer was reported in
BRCA1/2 mutation carriers exposed to low dose diagnostic
radiation under 30 years of age [122]. Whether ATM heterozygotes
have an increased risk of radiation effects continues to be debated,
but better technology and study design are improving the quality
of studies. Women's Environmental, Cancer, and Radiation
Epidemiology (WECARE) is a population-based study of cases
with contralateral breast cancer and matched controls with
unilateral breast cancer. WECARE showed women carrying rare
missense variants in ATM may have an increase risk of IR-induced
breast cancer [123].
Although studying mutation carriers is of interest, studies need
to be very large to have sufﬁcient statistical power because of the
low prevalence of individual mutations. Therefore, research has
tended over the past 10 years to focus on identifying the common
genetic variants seen in >1% of the population (SNPs) for which
there is growing evidence of functional impact. The quality of SNP
biomarker discovery in the IR ﬁeld has improved since the Pernot
publication aided by the establishment of the Radiogenomics
Consortium [124] and the development of reporting of guidelines
for radiogenomic studies [120]. Supplementary Table 3.3.2 lists
recent publications involving >1000 participants that investigated
SNPs associated with IR late effects.
Regarding SNPs associated with susceptibility, the WECARE
study investigated 152 SNPs in activators and downstream targets
of ATM (CHEK2, MRE11A, MDC1, NBN, RAD50, TP53BP1) in relation to
IR exposure and contralateral breast cancer risk. Carriers of a
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breast cancer risk than unexposed carriers [125].
There has also been a number of GWAS since the Pernot
publication. Large cooperative GWAS outside the IR ﬁeld highlight
the potential to identify a large number of SNPs, with individual
variants having small effect sizes but together accounting for a
meaningful proportion of susceptibility for a trait/disease [126].
The radiogenomic GWAS carried out to date show the potential
to identify SNPs associated with IR effects and susceptibility
(Supplementary Table 3.3.2 and references therein). For example, a
variant in PRDM1 was associated with second malignancies in
individuals who underwent radiotherapy for Hodgin’s lymphoma
as children [127]. Interestingly the gene encodes a protein involved
in the immune response to viral infection. It was suggested that
PRDM1 might be a candidate tumour suppressor gene mediated by
IR exposure, which raises the possibility that alterations in
immune regulation contribute to increased risk [128]. The GWAS
involved younger subjects where the effect size for genetic
susceptibility should be stronger (less masked by environmental
inﬂuences such as smoking) thus increasing statistical power and
reducing the sample sizes required [128].
Genetic studies are identifying SNPs associated with IR late
effects and susceptibility and more will emerge over the next ﬁve
years. Future studies are likely to explore other types of genetic
variation that might be important: CNV, insertions and deletions,
mitochondrial DNA variants and germline methylation. It might
also be useful to investigate whether the SNPs associated with
other endpoints relevant for IR epidemiology (e.g. cancer
susceptibility, cardiovascular disease and cataracts) are associated
with IR susceptibility.
It is anticipated that a future germline variant epidemiology
biomarker would be a polygenic risk score based on genotyping
tens to a couple of hundred of genetic variants. A blood or saliva
sample would be required and the results would be generated
rapidly in laboratories that are accredited to carry out genetic
testing. Biomarkers related to genetic variants have promise for
use in identifying individual risks for late effects and susceptabiltiy
in epidemiology studies. The challenge lies in designing studies
with sufﬁcient statistical power and identifying cohorts with the
data and samples required.
3.4. Biomarkers related to induced mutations
Whilst it is well established that IR is a mutagenic agent,
whether IR induced tumours have a speciﬁc mutation proﬁle
remains to be fully established. Mutational signatures have been
identiﬁed using whole exome sequencing in mouse models of
second malignant neoplasms mutational signatures [129] and new
ﬁndings using whole genome sequencing have unraveled a speciﬁc
pattern of mutations in IR associated human tumours [130]. Two
signatures of somatic mutations were found irrespectively of the
tumour type. Both extra genome-wide small deletions (1–100 base
pairs), often with micro-homology at the junction, and a signiﬁcant
increase in balanced inversions were detected. These distinctive
mutational signatures could explain the carcinogenic potential of
IR.
As discussed in Section 3.1.4 one of the few examples of a
possible IR associated genetic alteration is the gain of chromo-
somal band 7q11.23 in PTC in young patients exposed to 131I from
the Chernobyl fallout [131]. An unbiased genome wide survey of
germline mutations induced in mice after parental exposure to IR
was recently conducted [132], showing a signiﬁcantly higher
frequency of de novo CNVs and insertion/deletion events in
offspring of exposed fathers, as well as over-representation of
clustered mutations in the spectrum of induced de novo single
nucleotide variants. Whether this ﬁnding can be translated into asignature speciﬁc to IR exposure suitable for use in molecular
epidemiological studies to, for instance, classify tumours as IR
induced will be a future challenge.
3.5. Biomarkers related to transcriptional and translational changes
3.5.1. Biomarkers related to changes in RNA levels
A substantial number of recent studies have reported gene
expression signatures for IR exposure biodosimetry identiﬁed
using different classiﬁcation models like k-Nearest Neighbors,
Nearest (Shrunken) Centroids or Random Forests (Supplementary
Table 3.5.1.1), and validated the IR-responsiveness of such
signatures with ever decreasing doses (Table 2). These studies
have been made possible by many technological advances,
including; customized qRT-PCR arrays [133] or multiplex qRT-
PCR assays [134,135], which allow rapid PCR ampliﬁcation of a
signiﬁcant number of genes. Other technologies include the
Nanostring [134,136] and Chemical Ligation Dependent Probe
Ampliﬁcation [137,138] methods, with the added advantage that
they do not require prior complementary DNA synthesis. These
advances, which would allow targeted screening of small gene
signatures (typically <100 genes) as opposed to genome-wide
technologies, are appropriate for high-throughput screenings in
the situation of a large-scale event [139]. The recent use of exon-
level microarrays to evaluate genome-wide IR-induced gene
expression and alternative splicing in different experimental
models has revealed that a number of genes express transcript
variants in response to IR [23,140–142] which could prove to be
highly speciﬁc IR biomarkers (further discussed below).
Most, if not all, of such studies have identiﬁed very similar gene
signatures, despite differences in the subjects, IR doses, dose rates,
radiation qualities, cell/tissue types, sampling times and gene
expression platforms used (Table 2). For instance, in a comparison
of four studies using different IR sources and biological samples
(gamma-rays on whole blood, X-rays on PBMCs, alpha particles on
PBMCs and gamma rays on primary keratinocytes and ﬁbroblasts)
[23] 14 genes showed dose-dependent induction in all studies:
DDB2, POLH, MDM2, RPS27L, FDXR, CCNG1, TRIAP1, SESN1, FBXO22,
PPM1D, ANKRA2, CDKN1A, TRIM22, and BBC3. This demonstrates
the robustness of these signatures and their suitability as IR-
exposure biomarkers. Indeed, a recent NATO biodosimetry study
showed that single genes as well as gene signatures could be used
to estimate exposure of blood samples to IR doses of 0.1–6.4 Gy
with a similar accuracy and sensitivity as established cytogenetic
assays [137]. Importantly these signatures, which have mostly
emerged from studies involving ex vivo irradiated blood samples,
are also applicable for estimating exposures in radiation therapy
patients [139,143,144]. Changes in expression levels of some of
these genes up to 48 h after irradiation have been demonstrated.
Although this is a short time period for epidemiological studies, it
would be sufﬁcient for use in a radiological accident. Moreover,
since the transcriptional responses of individual genes display
different kinetics, one can envisage that gene expression signa-
tures could also be used to accurately predict not only the dose, but
also the time since exposure (Macaeva and Quintens, unpublished
data). In this respect, the use of a signature consisting of a number
of different genes, each with their maximum response at a
different time point offers a signiﬁcant advantage over a single
gene biodosimeter.
Several studies have shown dose-dependent changes in gene
expression after exposure to doses as low as 5 mGy (Table 2)
[135,145]. Exposure to 5–25 mGy mostly induced genes involved in
metabolic processes and chromatin organization, while the p53-
mediated pathways and DDR were mostly activated at doses of
25 mGy and above [145]. This is attributed to the fact that at low
doses a DSB is not induced in every cell. A linear dose-response
Table 2
Gene expression studies investigating the transcriptional response to low-dose (<100 mGy) radiation exposure.
Dose (mGy) Dose rate Quality Cell type Organism Time
point (h)
Genes reported to be responsive to 100 mGy and
validated by qRT-PCR
Reference
0, 100, 2500 Not reported 4.5 MeV
protons
3D epidermis
model
Human 4, 16 and
24
ADAMTS1, APOBEC3A, ATF3, BCAS3, CDK9,
CYP1B1, GPRC5A, IGF2, PSCA, PTGS2, ROR1
[290]
0, 10, 25, 50, 75, 100 1.5–4 cGy/min gamma-
rays
lymphoblastoid
cell lines
Human 4 ASCL3, CD164, GGH, LIPA, PAM, PPT1, SCAMP1,
SSR1
[291]
0, 20, 100. 500,
1000, 2000, 4000
0.7 Gy/min, 0.0286 Gy/min
for 20 and 100 mGy
gamma-
rays
PB Human 6, 24, 48 FDXR, PFKFB3 [147]
0, 10, 25,50 10 mGy/min X-rays PBMC Human 24 and 48 Not reported [292]
0, 100, 1000 0.5 Gy/min X-rays 3D skin model Human 5 min, 3, 8
and 24
Not reported [293]
0, 50, 1000 3 cGy/min X-rays PB Human 8 CCR4, GNG11, PF4, POLH [294]
0, 5, 10, 20, 50, 75,
100
4.9 mGy/min X-rays PB Human 2 and 24 C12orf5/TIGAR, CCNG1, DDB2, GADD45A, FDXR,
MDM2, PHPT1
[148]
0, 5, 10, 25, 50, 100,
500
50 mGy/min gamma-
rays
CD4+
lymphocytes
Human 2.5, 5, 7.5
and 10
Not reported [295]
PB: Peripheral blood; PBMC: Peripheral blood mononuclear cell.
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FDXR, GADD45A, and PHPT1 being signiﬁcantly differentially
expressed at doses  100 mGy. Such results highlight that gene
signatures may well be applicable for biodosimetry purposes in the
low-dose range.
Amongst the genes that have been identiﬁed as radiation-
responsive, FDXR has emerged as accurate and reliable for dose
estimation in human blood samples [137,146–148]. FDXR, also
known as adrenodoxin reductase, is a mitochondrial ﬂavoprotein
that transfers electrons from NADPH to mitochondrial cytochrome
P450 enzymes (Fig. 1), mediating the function of ferredoxin [149].
It is involved in multiple processes mediated through p53 as well
as ROS associated apoptosis [150,151]. Quantitatively, FDXR is one
of the most radiation-responsive genes (e.g. up to 46–fold
upregulation 24 h after 4 Gy irradiation in human blood), with
relatively small inter-individual variability. This allows easy
discrimination between high and low dose exposure [148]
although a saturation dose effect occurs at doses >2 Gy. FDXR
has been validated as a sensitive gene to assess dose in irradiated
patients in two large scale studies involving nine labs [137,139] and
found to be the best gene for dose assessment by four of the seven
partner laboratories in a NATO led exercise [137]. A RENEB inter-
laboratory comparison exercise also found it was the best gene for
dose estimation for ex vivo irradiated blood from 12 donors and, for
the ﬁrst time, could distinguish blood samples of prostate cancer
patients exposed to 0.009–0.017 Gy (ﬁrst fraction only, partial body
exposure) [139].
One of the recurrent questions for the use of an endpoint as a
low dose IR biomarker is its speciﬁcity. As the genes often found in
IR signatures are responsive to DNA damage, smoking is a potential
confounder of concern. Paul and Amundson showed that smoking
did not affect the predictive performance of their 74-gene IR
response signature in peripheral blood, and only one gene was
differentially expressed between males and females [152].
Importantly, this signature classiﬁed 98% of the samples correctly
according to dose (0, 0.1, 0.5, or 2 Gy), irrespective of gender and
smoking. The effect of inﬂammatory stress has also been
investigated. Whilst a panel of eight genes which, in combination
with one phosphoprotein marker, could classify human peripheral
blood samples with an accuracy of 88% depending on their IR
exposure (0 or 2 Gy), inﬂammation status, or both [153] it remains
to be established whether this will still be the case after lower
exposure doses. A study in mice found that many genes would
retain their potential utility as IR biomarkers regardless of whether
the animals were treated with LPS or granulocyte-colony
stimulating factor over a dose range of 0.2–0.6 Gy [144,154].3.5.1.1. IR induced alternative splicing. As discussed above, recent
studies using exon-level microarrays to examine transcript
changes have shown that a large number of genes, including
FDXR (Fig. 1), express transcript variants in response to IR [23,140–
142]. In the case of IR, this seems to result mostly from alternative
promoter usage by p53 [140,142], although changes in RNA
polymerase elongation [155] or interactions between the RNA
polymerase and splicing factors [156,157] may also be involved, as
has been shown for other genotoxicants, such as UV irradiation.
However, the speciﬁcity of these alternative splicing events for
exposure to IR compared to UV has yet to be established.
Importantly, it was demonstrated that gene and exon signatures
from PBMCs were equally suitable for correctly (100% accuracy)
classifying samples that were either not irradiated, irradiated with
a low dose (0.1 Gy) or a high dose (1 Gy) of X-rays. As IR-induced
differences in expression were more pronounced at the exon-level
compared to genes, exon signatures may potentially be useful
exposure markers for doses below 0.1 Gy [23]. IR-induced
expression of transcript variants may explain differences in
expression levels obtained by primer- or probe-based assays
between different studies, which could result from the interro-
gation of more or less responsive exons. Therefore, when using
such assays for biodosimetry purposes, it is important to target the
correct combination of exons.
Further investigations into the transcriptional IR response of
cells and tissues using, for instance, next-generation sequencing of
transcriptomes, would be very valuable for identifying the exact
sequence identity of IR-induced splice variants. Although not
immediately applicable for biomarker purposes, the functional
characterisation of these variants would signiﬁcantly increase our
understanding of the molecular mechanisms involved in the (low-
dose) IR response.
3.5.1.2. Transcriptional biomarkers of susceptibility/late or persistent
effects. Although most of the work on transcriptional IR
biomarkers has focused on ﬁnding biomarkers of IR exposure,
several reports have attempted to identify either pathways or gene
signatures predictive of susceptibility and late health effects.
3.5.1.2.1. Transcriptional biomarkers of susceptibility. The ATM/
CHEK2/p53 pathway responds to DSBs, leading to cell cycle arrest
and DNA repair through the transcription of genes including
CDKN1A (p21) and DDB2 (Fig. 1). Failure to undergo repair may
result in enhanced apoptosis (e.g. via BBC3 (PUMA)), permanent
cell cycle arrest or senescence. Using mouse strains differing in
copy numbers of Atm, Trp53 (p53) and Chek2, IR-induced changes
in transcription of the p53 target genes Cdkn1a, Puma and Sesn2
Fig. 1. PUMA and FDXR mRNAs are biomarkers of respectively cancer susceptibility and radiation exposure linked to the ATM/CHEK2/P53 pathway.
FDXR receives electrons from NADPH and initiates the electron-transport chain for cytochromes P450 within mitochondria. PUMA localizes to the mitochondria and is
involved in the activation of apoptose. A) Ex vivo irradiation of whole blood (2 Gy) leads to early variations in PUMA mRNA (2 h post exposure) compared to control (0 Gy)
samples that may potentially be used as susceptibility biomarker for cancer. The level of PUMA transcriptional up-regulation is associated with the activity level of the ATM/
CHEK2/P53, an essential DDR pathway component (adapted from [134]). B and C) At low (10–100 mGy) and high (1–4 Gy) doses, in vivo and ex vivo irradiation of human blood
or T-lymphocytes leads to a strong FDXR mRNA level increase 24 h after irradiation. FDXR has the potential to be used as a biodosimeter (adapted from [135]). D) FDXR is one of
the most extensively radiation-induced spliced genes in blood cells. The sensitivity of the radiation-induced signal is dependent on the exon targeted by the primers/probe
combination (adapted from [23]).
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number, with the best correlation being seen for Puma [139,163].
Atm/Chek2/p53 pathway activity as assessed by the Puma response
correlated well with cancer incidence in mice with differing Trp53
gene copy number [158]. The mouse data was validated in humans
by examining mitogen stimulated T-lymphocyte cultures from
healthy donors, ATM mutation carriers and Li Fraumeni Syndrome
patients following irradiation [163]. PUMA upregulation after
irradiation was observed, with the AT case having a very weak
response and AT heterozygous carriers and LFS samples showing
an intermediate response. Inter-individual variability in the
activity of the ATM/CHEK2/p53 pathway was assessed in blood
samples from the same 32 healthy donors irradiated ex vivo with
2 Gy. PUMA gene expression examined at 2 h was compared against
the previously obtained mouse p53 copy number linear curve and
was found to be consistently over- or under-expressed in
comparison to the mean for speciﬁc donors, suggesting natural
variation between individuals (Badie personal communication).
These data demonstrate that an integrative biological approach
monitoring IR-induced changes in key p53 regulated genes in
blood samples can provide a read-out of DDR pathway activity,
with a potential link to susceptibility. P53-independent genes have
also been proposed to predict susceptibility to IR. Forrester et al.
identiﬁed an 8-gene signature (DDIT4L, DPT, FBN2, FST, GPRC5B,
NOTCH3, PLCB1, and SGCG) that could potentially predict ﬁbrosis in
patients prior to radiotherapy [159].
3.5.1.2.2. Transcriptional biomarkers of health effects. There are few
studies on the transcriptional changes linked to health effects. For
instance p16INK4A may be a potential biomarker for the long-term
health effects of childhood radiotherapy in acute lymphoblastic
leukaemia survivors [160]. p16INK4A is a marker of senescence and,although skin biopsies were taken on average 12 years after IR
therapy, its expression was increased in irradiated skin compared
to non-irradiated skin from about half of these patients.
Radiation workers (in medicine or industry) generally receive
low doses of IR protracted over the duration of their work. In
Mayak nuclear workers, who received higher doses in early years
than most nuclear workers, associations were observed between
gene expression proﬁles in the peripheral blood and chronic non-
cancer disease outcomes. Twelve mRNAs and nine miRNAs were
signiﬁcantly associated with six different diseases, particularly
those related to atherosclerotic processes. These associations were
gender- and dose-dependent and 26 potential confounders were
considered including age at exposure, age at biosampling,
demographic, social habits, data related to health status [161].
Other studies found long-term changes in gene expression in
medical workers [162,163], and in thyroid cancer tissue from
patients exposed to Chernobyl fallout [164,165]. Although the
evidence from these studies remains preliminary and many from
high dose exposures, they highlight the potential for gene
expression signatures as biomarkers of late effects of IR exposure.
3.5.2. Biomarkers related to changes in protein levels
As discussed in [9], the identiﬁcation of IR-associated protein
biomarkers is challenging because of the time and dose-dependent
variation in protein expression. A number of recent proteomic
studies have investigated high dose IR induced alterations in the
proteome of different bio-ﬂuids including serum and urine with
the aim of identifying biomarkers of exposure and IR sensitivity
applicable to radiological emergencies For instance Chaze et al.
[166], found an increased up-regulation of genes involved in the
glycolysation in liver and increased serum cytokines, suggesting a
systemic response to local irradiation of the skin to 20, 40, and
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Factor X and Panththenate Kinase 4) in blood samples allowed
discrimination up to 1 month following exposure to <2 Gy and
>10 Gy in breast cancer patients, although differences at <2 Gy
were subtle [167]. Similarly [168] found that changes in serum
amyloid A (SAA) levels permitted a dose prediction model to
discriminate 1 Gy from 2 Gy irradiated mice.
To investigate the mechanisms underlying individual IR
sensitivity Skiöld et al. [169] compared the proteome proﬁles of
leukocytes from ex vivo irradiated whole blood following 0, 1, or
150 mGy from normal responding and extremely radiosensitive
patients. Proteomics analysis showed unique proteomic signatures
separating the two groups at the basal level and after doses of 1 and
150 mGy. Pathway analysis suggested that the oxidative stress
response, coagulation and acute phase response are hallmarks of IR
sensitivity.
Although the literature after low dose IR remains limited these
ﬁndings indicate that IR causes detectable changes in the bio-ﬂuid
proﬁle at high doses and may differentiate radiosensitive
individuals even at low doses. The main questions that needs
addressing are; 1) whether the alterations in bio-ﬂuid proteins are
unique for IR exposure or whether they arise in more general
physiological states such as inﬂammation; and 2) whether the low
dose results are conﬁrmed.
3.5.3. Correlations between proteins and mRNA and pathway
mapping
The last two decades have seen an important emergence of
technologies which allow high-throughput “omic” analyses. While
originally analysed separately, we have now reached the era of
systems biology, in which these quantitative data-sets can be
integrated. Studies investigating genome-wide correlations be-
tween mRNA and protein expression levels in different organisms
found that mRNA levels predict only 30–50% of cellular protein
levels [170], although higher correlations have also been observed
[171], highlighting the importance of post-transcriptional regula-
tory processes and measurement noise that contribute to protein
expression levels [172]. Indeed, correlations between mRNA and
protein levels are signiﬁcantly higher when considering genes that
are differentially expressed after a treatment [173,174]. Also,
removing experimental noise increases mRNA-protein expression
correlations [170].
As discussed above, both transcriptomic and proteomic
analyses have identiﬁed IR biomarkers, albeit mainly for exposure.
However, mRNA and protein levels are rarely measured in the same
study, nor have they been combined for the purpose of predicting
unknown IR doses or as markers for IR sensitivity or late effects. A
recent study analysed protein phosphorylation (H2AX, p53 and
ATM) and gene expression of DDR genes (ATF6, BAX, BBC3, DDB2,
MDM2 and TP53) in T-lymphocytes from patients before and after
(24 and 48 h) single-photon emission computed tomography
myocardial perfusion imaging [175]. Patients received effective
doses of 18.2  10.6 mSv. Only a small number of these patients
showed increased protein phosphorylation associated with
increased expression of DDR genes (BAX, DDB2, MDM2 and
TP53). The other patients either had no change or decreased
expression of DDR genes.
Another possible interaction between different molecular
layers is that of the microRNome and proteome. Indeed, the
function of microRNAs is to either degrade RNA messengers or
prevent translation of their targets, thereby negatively inﬂuencing
protein expression levels. Studies investigating correlations
between microRNA and protein expression proﬁles in response
to IR in different experimental models [176–178] found that
moderate IR doses (200–500 mGy) affected expression of somemicroRNAs (see Section 3.6.2) while some of their predicted
targets were oppositely regulated at the protein level.
In an important effort towards data integration following
exposure of an in vitro 3-D human skin model to low IR doses [179],
the temporal response (from 1 to 72 h) of dermal and epidermal
layers to 100 mGy of X-rays was investigated using transcriptomic,
proteomic, phosphoproteomic and metabolomic platforms. Be-
sides cell cycle regulation and DNA damage signaling, mostly
affected at the mRNA level, matrix regulation and oxidative stress
response pathways were also modulated. The latter was predicted
to be primarily regulated through the transcription factor SP1,
which was shown to be activated (phosphorylated) in a dose-
dependent way [179]. Such studies are in their infancy but
demonstrate the power to identify pathways with expression
changes modulated by low dose IR, which may represent potential
IR biomarkers. They also highlight the dynamic nature of changes
and the challenge of identifying a signature that is able to resolve
both dose and time since exposure.
3.6. Biomarkers related to epigenomic modiﬁcations
3.6.1. IR induced protein post-translational modiﬁcations
The analysis of IR-induced changes in global proteome proﬁles
highlights the broad range of alterations in the cellular processes
that are regulated by PTMs including phosphorylation, acetylation,
ubiquitination, and neddylation. The regulatory network of DRR is
one of the best examples of a gene network regulated by PTMs
which impact on protein activity and stability rapidly and
independently of the changes in de novo protein synthesis
[180,181] of which gH2AX is one of the most studied examples
(Section 3.2.2).
Recent advanced comparative proteomics methods applied in
radiation biology [182] enable the analysis of PTM status after IR
exposure. There are solid data describing the PTMs after high-dose
exposure [183,184] but studies investigating PTMs after low-dose
exposures are scarce, experimentally challenging and, as for high
dose proﬁling, may be limited by the model system under
investigation. For instance, the IR induced alterations in proteins
found in a human skin model after IR doses (0.03, 0.1 and 2 Gy)
were dispersed throughout the entire skin tissue with altered
protein phosphorylation status being found in each layer with the
majority corresponding to skin structural proteins (such as
keratins and desmosomal proteins) involved in maintaining tissue
integrity [185]. This suggests that the skin as a whole responds to IR
and different epithelial layers may have different roles to maintain
skin structural and genomic integrity following exposure to such a
tissue stress.
Acetylation has mainly been studied in the context of
transcriptional activity and as a regulator of chromatin accessibili-
ty through histone modiﬁcation after high dose exposure to IR. For
instance a hypoacetylation of H3K9, H3K56, H4K5, and H4K16 in
lymphoblastoid cell lines is seen 15 min,1 h and 24 h after exposure
to 2 Gy and 10 Gy which may play a role in the increased cellular
radiosensitivity [186]. The DDR is also regulated by the ubiquiti-
nation of key proteins [187]. High dose IR-induced DDR
ubiquitination is as prevalent as phosphorylation and signiﬁcantly
more common than acetylation (see for instance [188]). It has been
shown that protein ubiquitination is associated with the recruit-
ment of DNA repair factors [189] and also the activation of key
response proteins such as ATM. In addition to ubiquitin, it has been
shown that the ubiquitin-like proteins such as small ubiquitin-like
modiﬁers (SUMO), and neural precursor cell expressed develop-
mentally down-regulated protein 8 (NEDD8) play essential roles in
the cellular response to DNA damage [180]. However, such
modiﬁcations have not been examined after low doses and it is
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exposure or responses.
These examples illustrate how PTM studies may lead to
identiﬁcation of IR-speciﬁc-signatures to serve as possible
biomarkers of exposure. Although the identiﬁcation of PTMs is
an anticipated goal in many clinical studies, the complex and
sophisticated methodology necessary for a successful PTM analysis
makes such studies challenging particularly in an epidemiological
setting where sample collection with respect to exposure is often
limited. Therefore, screening of potential IR-induced post-transla-
tional biomarkers with high conﬁdence, reproducibility and
accuracy using different biomaterials still remains a vision of
the future.
3.6.2. Non-coding RNAs
ncRNAs are emerging as important biological molecules [190].
They are grouped broadly into two classes based on transcript size:
small ncRNAs and lncRNAs. The small ncRNAs include miRNAs that
are 22 nucleotides long and are involved in the regulation of
mRNAs following their transcription [191,192].
miRNA expression proﬁles are tissue-speciﬁc, can be modulated
following exposure to both low and high LET irradiations and have
potential as biomarkers of IR exposure [176,193–199] (Supple-
mentary Table 3.6.2 and references therein). miRNA is more stable
than mRNA, can be extracted from parafﬁn-embedded material
[195], and is detectable in biological ﬂuids after exposure to IR
[196,197]. Although most studies to date involved blood samples,
miRNAs can be measured in many biological ﬂuids including saliva,
tears, seminal ﬂuid, breast milk and cerebrospinal ﬂuid [200]. Most
published data described the impact of high and moderate doses of
IR and reported changes in a short time scale (minutes to hours)
after exposure. There is a lack of data describing the effects of low
doses and long-term effects (Supplementary Table 3.6.2).
LncRNAs also have developmental and tissue-speciﬁc expres-
sion patterns, and aberrant regulation in a variety of diseases,
including cancer [190,201]. LncRNAs are mRNA-like transcripts
ranging in length from 200 nucleotides to  100 kilobases lacking
signiﬁcant open reading frames. These long polyadenylated RNAs
do not code for proteins, but function directly as RNAs, recruiting
chromatin modiﬁers to mediate transcriptional changes in
processes ranging from X-inactivation (lncRNA XIST), imprinting
(lncRNA H19) to genome-wide chromatin reprogramming (lncRNA
HOTAIR) [202].
Evidence that IR exposure elicits dose- and time-dependent
changes in the expression of ncRNAs that are inﬂuenced by the
genetic background has come from studies monitoring the
expression of 19 miRNAs and 3 lncRNAs [158] in stimulated
human T lymphocytes obtained from two healthy donors and one
patient with AT with the observation that FAS-AS1 lncRNA is up-
regulated by IR exposure in an ATM-dependent fashion.
Exposure to low-dose IR also causes transiently elevated
expression of the lncRNA PARTICLE [203]. PARTICLE is a tuner of
cellular methylation following IR exposure. Signiﬁcantly, the effect
of PARTICLE in limiting the time and extent of the IR-induced
increase in DNA methylation is more pronounced at lower than
higher doses providing evidence of a non-linear effect. Increases in
PARTICLE expression were noted in plasma samples from post-IR
therapy patients [203]. Further experiments are needed to assess
whether it may be a suitable biomarker of low dose exposures.
Recently Macaeva et al., 2016 suggested lncRNAs as potential IR
biomarkers. For instance PAPPA-AS1, a lnc-RNA transcribed from
the opposite strand of the radiation-responsive gene PAPPA, is
among the 20 best genes to distinguish between exposure to 0, 0.1
and 1.0 Gy [23].
In terms of future developments, apart from the need for more
robust studies at low doses, an improvement in detectiontechnologies and the development of dedicated biosensors is
crucial. The future of ncRNA biomarkers is promising [204] and we
are only at the very beginning of our understanding of their
biological roles.
3.7. Other biomarkers
3.7.1. Biomarkers associated with RedOx imbalance
It is well accepted that oxidative stress, caused by the imbalance
between the production of ROS or RNS species and their
elimination by antioxidant defense systems, contributes to
pathogenic mechanisms of several diseases. The markers of
oxidative modiﬁcations associated with exposure to IR in
experimental models and in humans were reviewed by Pernot
et al. [9] and more recently by [81]. These include biomarkers of
elevated ROS levels such as 8-oxo-dG (Section 3.2.3), markers of
antioxidants such as catalase expression, arising as a consequence
of increased ROS, and markers of enzymes generating ROS. Studies
linking IR exposure to the oxidation of biomolecules continue to
emerge but few have investigated low-dose exposures. In mice
with doses of 50–75 mGy, anti-oxidative effects were observed
with increased expression and function of renal Nrf2 transcription
factor and its target anti-oxidant enzymes SOD1, HO-1 or NQO-1
[205,206]. A study of cognitive defects in irradiated mice showed a
decrease of total malondialdehyde-modiﬁed protein content in the
hippocampus at 1 Gy [178] and the analysis of S-nitrosothiols, a
post-translational modiﬁcation of proteins, by mass spectrometry
in brain, liver and plasma showed a decreased level after exposure
to 100 mGy [207] suggesting that markers of redox imbalance
might be associated indicative of cognitive defects. Persistent (40
week) increases in protein carbonylation in the cardiovascular
system after a single heart dose to C57BL/6 mice were detected
after exposure to 2 Gy but not after 0.2 Gy [176].
Thus whilst RedOx balance markers are important for the
evaluation of IR induced effects and disease and are induced by
high dose IR, further studies are needed at low-dose effects to
assess their usefulness as indicators of damage or adaptive
responses in molecular epidemiological studies.
3.7.2. Metabolites and metabolomics
Metabolomics has potential for the development of early
biomarkers of exposure but the ﬁeld is still in its infancy. Major
obstacles in global metabolomics proﬁling are the identiﬁcation of
unknown compounds [208]; the sheer complexity of the
metabolome, requiring advanced equipment and data processing
tools [81]; and the lack of IR speciﬁcity of some metabolic
biomarkers [209]. Nevertheless, this technology is powerful if used
in deﬁned conditions [81] especially if combined with other
“omics” technologies [179] and is particularly amenable for use
with urine samples. In addition, some changes can be detected
before the onset of any clinical symptoms suggesting that they may
be biomarkers for early disease onset [210].
Two technologies currently dominate metabolomics research:
NMR spectroscopy and MS. Although NMR has many advantages
(such as non-selectivity, lack of sampling bias and reproducibili-
ty), it is hampered by low sensitivity, requiring large amounts of
sample. MS-based methods on the other hand are highly sensitive
and incorporate upstream online analytical separation steps for
metabolites, including LC, GC, or capillary electrophoresis. A
broad spectrum of IR-induced metabolite alterations have been
detected although many of the studies have used high dose
treatments (Supplementary Table 3.7.1). Mitochondria are an
established target of IR [211–214], and many metabolite
biomarkers are directly or indirectly involved in mitochondrial
metabolism.
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clinical studies have shown the ability of metabolomic approaches
to detect differences in urinary proﬁles related to dose, dose-rate
and IR quality [215–218]. Gender speciﬁc differences were found in
non-human primates [219] after doses > 6.5 Gy which persisted up
to 7 days post-irradiation [220] and cancer patients undergoing
total body irradiation [221]. Whether such differences exist after
low dose exposures remains to be established.
Only a few IR metabolomics studies used serum samples but
they employed high doses [222–224]. With improving technology,
alterations were detected in rat serum 24 h after irradiation with
0.75 Gy gamma rays [225] and proﬁles after lower dose exposures
are now technically feasible.
3.7.2.2. Metabolite biomarkers in cells and tissues. Whilst
metabolomic studies of body ﬂuids reﬂect several different
biological processes, only the study of cells and tissues will
address tissue-speciﬁc IR exposure and effects.
Time- and dose-dependent changes were measurable in a full
thickness human skin tissue model irradiated with 0.03 or 0.1 Gy
and assessed at 3, 24 and 48 h [226]. While no changes in extracted
metabolites were observed 3 h following irradiation with 0.03 or
0.1 Gy, by 48 h changes were seen at all doses. These metabolites
have potential as biomarkers of radiation exposure. Analysis of the
metabolites dysregulated at 48 h following low dose exposure
identiﬁed pertubations in pathways involving DNA/RNA damage
and repair, and lipid and energy metabolism.
Human B lymphoblastoid and ﬁbroblasts cells were used to
identify low dose responsive metabolites 10 h after exposure of
0.02, 0.1, and 1.0 Gy X-rays [227]. Measurable changes were seen at
0.1 Gy but not 0.02 Gy and there were marked differences between
the cell types. Li et al. investigated the effect of total body gamma
IR (0.1, 0.5 and 3.0 Gy) on T cell activation and metabolism in
irradiated male C57BL/6 mice at 4 h, 1 week, and 2 week time
points [228] The T cell receptor-activation induced metabolomics
changes were altered in a radiation- dose- and time-dependent
manner. Effects were seen at 0.5 Gy but not at lower doses,
consistent with ﬁndings of a reduced percentage of naïve T cells
reported in the A-bomb cohort [81,229]. It is not known whether
these metabolomics changes contribute to the known immune cell
stimulatory effect of low dose IR.
3.7.3. Biophysical markers
There is interest in the development of biodosimeters that
measure physical or chemical changes in non-biological (e.g. cloth,
glass, plastic etc) or biological (e.g. nails, teeth, hair) samples after
IR exposure. The relatively stable chemical species generated are
detectable by, for instance, EPR spectroscopy. A challenge for ex
vivo EPR nail dosimetry is the overlap between the mechanically
induced signals produced by cutting nails and the IR induced
signals. This overlap can, to some extent, be overcome by spectral
ﬁtting (see for example [230]) and identifying stable IR-induced
radical(s) [231]. To date this technology was used to estimate high
dose localised exposures to the hands (>10 Gy) after severe IR
accidents (see [231] and references there in). EPR on tooth enamel
was also used to measure exposure to accidental noble gas release
from the Mayak Production Association, natural background IR
(0.7  0.3 mGy annually to tooth enamel) and routinely released
noble gases in Ozyorsk citizens (see for instance [232]). It has also
been used in external dose reconstructions in Chernobyl accident
recovery workers [233,234] and in people living near the
contaminated Techa River [235]. In the latter studies, with
relatively high doses, both EPR and FISH based dose estimates
were comparable and agreed with estimates of external and 137Cs-
internal exposures calculated with the Techa River Dosimetry
System. Alternative EPR test materials also show promise, e.g.,glass from the touch screens of smart phones, but there are
technical issues, such as the variability of samples from different
smart phones and environmental conditions (see for example
[236]) that must be resolved.
3.7.4. Circulating DNAs
ccfDNA is being explored as an early biomarker of cancer [237],
and is of interest as a potential biomarker of IR exposure. Short
DNA fragments, resulting from IR induced DSBs or released from
cells as a result of physiological processes, can be extracted from
blood and detected using qPCR techniques. After in vivo irradiation,
atomic force microscopy can characterise the size distribution of
individual DNA fragments extracted from blood, with high LET
neutrons producing shorter DNA fragments than low LET electrons.
This may be of interest for the development of exposure
biomarkers which identify radiation quality. Two studies recently
reported ccfDNA levels in populations exposed to low IR levels.
Borghini et al. [238] found no correlation between recorded
lifetime dose and ccf-DNA or mtDNA fragments in a subset of 15
interventional cardiologists. However, ccf-DNA and mtDNA frag-
ments tended to be signiﬁcantly increased in interventional
cardiologists exposed to higher doses (52 mSv, median lifetime
cumulative dose) compared to lower levels and controls. In
contrast Korzeneva et al. [239] found decreased plasma ccfDNA
concentrations in individuals exposed to low-dose gamma-
neutron or tritium beta-radiation. Thus whilst the quantiﬁcation
of ccfDNA represents an attractive minimally invasive approach for
developing IR biomarkers, it is too early to comment further on its
potential.
3.7.5. DNA repair capacity measurements as biomarkers of
susceptibility
There is substantial evidence for inter-individual differences in
DNA repair capacity (reviewed in [240]). This ability can be
assessed directly using gH2AX or other DNA repair foci measure-
ments (see Section 3.2.2) or indirectly by measuring mutagen
sensitivity and both approaches have been used in a number of
epidemiological studies. Assays in whole cells address the
complexicity of the DNA damage response that is affected by
genetic, epigenetic and transcriptomic modulators. However such
assays do not provide direct mechanistic information about the
genotoxic lesions or the modulated pathways.
Numerous methods have been developed for measuring DNA
repair capacity directly which, as reviewed by Nagel et al. [240],
have strengths and weaknesses. Some have the advantage of
measuring repair of genomic DNA in intact cells but are often
labour intensive and show large inter-laboratory variation, thus
limiting their application in large-scale epidemiological studies.
The widely used comet assay is associated with large inter-
laboratory variation (see for example [241]), limiting its usefulness
in multi-centre studies, particularly after low dose IR exposures. A
comet assay chip has been developed [242–244] with a 100-fold
higher throughput compared to the traditional assay but it requires
validation in inter-laboratory comparisons.
Single cell network proﬁling is another potential approach to
quantitatively measure DNA repair capacity in biological samples
by characterizing signaling responses at the single cell level using
multi-parametric ﬂow cytometry following exposure to a DNA
damaging agent. This approach has identiﬁed functional DDR
readouts in both NHEJ and HR pathways and has been explored for
predicting clinical outcome in oncology settings (see for instance
[245] and references therein). Further experiments are needed to
establish the speciﬁcity and sensitivity of such assays in terms of
responses to low doses of IR.
Host cell reactivation assays offer a powerful way to measure
DNA repair capacity in living cells and have been used in molecular
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benzo[a]pyrene diol epoxide induced DNA lesions [246]. However
this assay generally cannot assess the repair of lesions that do not
block the progression of RNA polymerases and is limited further by
the need for separate assays to measure individual DRC pathways,
or at more than one dose of DNA damage. A recently developed
multiplexed ﬂuorescence based ﬂow cytometric host cell reacti-
vation assay addresses certain of these limitations by using
different reporter plasmids to measure the repair of several doses
of multiple types of DNA damage in a single assay [240]. A next
generation sequencing based assay was also developed that
detects rare transcriptional mutagenesis events due to lesion
bypass by the RNA polymerase, providing two tools for exploring
relationships between global DNA repair capacity and disease
susceptibility.
Functional DNA repair signatures can also be measured using
protein extracts from cells or tissues making use of DNA
substrates containing deﬁned lesions. Using such an approach
the BER, MMR, direct reversal by MGMT, NER, NHEJ, cross link
repair and HR pathways were assessed in a number of
epidemiological settings (see [240] and references there in). In
addition an excision/synthesis repair assay using a biochip
carrying plasmids containing different types of DNA damage
typically repaired by different repair pathways assays has been
developed and tested using a variety of human samples. This
assays allows an individual’s DNA repair phenotype towards a
panel of lesions repaired by distinct repair pathways to be
determined (see for instance [247]). One major limitation of both
the HCR and biochip assays for assessing DNA repair capacity for
IR induced lesions is the need for repair substrates carrying
lesions representative of those found after both high and low LET
irradiation and in particular clustered lesions.
Another outstanding question with respect to assessing DNA
repair capacity is the choice of the most suitable biological
material. Variation between tissues has not been extensively
explored but for large scale prospective molecular epidemiological
studies the choice of tissue is often limited to viable cells isolated
from blood samples. However, the possibility of generating cells
representative of various human tissues by differentiating induced
pluripotent stem cells from skin ﬁbroblasts that can be obtained
from a single biopsy may become a reality in the near future and
opens up the possibility for large prospective epidemiological
studies investigating DRC in target tissues. Clearly such an
approach will require ethical reﬂection and logistical consider-
ations that to date have not been instigated at the European level.
3.7.6. Mitochondria as biomarkers for low dose IR exposure and effects
MtDNA is vulnerable to damage because, in comparison with
nuclear DNA it lacks protective histones, has a high exon to intron
ratio, has inefﬁcient DNA repair machinery [211] and is located
close to the mitochondrial respiratory transport chain, the most
important cellular source of ROS [248–251]. Changes in mitochon-
drial function and number after exposure of cells or tissues to high
IR doses have been found [252–254]. A sensitive measure of
mtDNA damage is the accumulation of the common deletion
generated during the processing of DNA damage within a 4977
base pair region ﬂanked by two 13 base pair repeats [255,256]. This
accumulation has been proposed as a sensitive marker for the
evaluation of low dose IR-induced effects. For instance, Schilling-
Tóth and coworkers have demonstrated an increase in common
deletion levels 72 h after exposure to doses of 0.1 Gy in both
primary and immortalized ﬁbroblast cell lines [257]. This is
however unlikely to be speciﬁc to IR as the common deletion is
often observed in diseases, such as the Kearns-Sayre syndrome,
that involve a premature aging process [258,259]. Despite this
limitation, because of the stability of this change, it may representa longer term exposure marker that warrants assessing in pilot
studies.
3.8. Biomarkers of internal exposures
Internal contaminations by radionuclides can occur in a
number of occupational, medical and environmental settings
and require the use of speciﬁc biomarkers to provide a qualitative
indication or a quantative assessment of absorbed dose to a speciﬁc
organ or tissue. Following intake, the distribution throughout the
body depends on the biokinetics and speciation of the radionu-
clide. The irradiation is protracted during the retention period of
the radionuclide and its relative biological efﬁciency depends on
the type of IR emitted. In addition, some radionuclides, for instance
U and other heavy metals, have potential for chemical and even
physical (e.g. in case of particle inhalation) toxicity.
3.8.1. Current techniques for the biological determination of exposure/
intake of internal emitters
Incorporated radionuclides emitting penetrating IR (X-rays, g
or energetic b) can be monitored directly using external detectors.
However this approach is not feasible for radionuclides emitting
only (or mainly) a or low energy b radiation. Intakes of U, Pu and
3H, among others, are usually monitored by in vitro analysis
involving excreta or other biological samples (urine, feces, nose
blow, nasal smear, saliva, rarely blood or biopsy). Dedicated models
combined with a scenario of exposure (e.g. time and route of
intake, physico-chemical form of the incorporated radionuclide)
are needed to evaluate intake and dose. The precision of the
assessed dose is strongly affected by the uncertainty of the
exposure conditions and the biokinetics of the radionuclide. For
most radionuclides and for medium to low levels of exposure,
radioactivity measurements in urine and blood are representative
of a recent exposure only, over a period depending on the decay
scheme and the biokinetics of the radionuclide.
In recent years, epidemiological studies of occupational
exposure to radionuclides have begun to beneﬁt from detailed
internal dosimetry protocols to evaluate annual organ doses from
bioassay monitoring data and information on the conditions of
exposure (see Supplementary Table 3.8.1 and references therein).
There is clear potential to improve, by integrating biomarkers of
exposure to radionuclides in epidemiological studies, the charac-
terization of the shape of the dose-response for cancers [260,261],
but also non-cancer diseases [262,263], and to improve the
knowledge of the effects of internal contamination [264] and of
radiation quality.
3.8.2. New biomarkers of exposure to internal emitters
The techniques currently being used for monitoring incorpo-
rated radionuclides present inherent limitations which results in
substantial uncertainties in internal dose estimates. New biomark-
ers are thus needed that would have longer persistence, and
provide information about the chemical speciation or the isotopic
form of the incorporated radionuclide, tissue-speciﬁc information
on radionuclide presence, quantity, or associated biological
damage.
Non-targeted approaches such as metabolomics, lipidomics
and proteomics have provided promising preliminary results for
new biomarkers of exposure to radionuclides, as demonstrated by
recent studies of uranium (lowest estimated calculated dose of
0.15 mGy in the kidney), 137Cs (lowest average cumulated dose of
4mGy) and 90Sr (lowest average cumulated dose of 1 Gy)
contamination in rats [216,217,265–267]. Translocations, complex
chromosomal rearrangements and micronuclei in peripheral blood
lymphocytes (see above) are also potentially useful to estimate
cumulated red bone marrow doses resulting from protracted
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high doses, although further work is needed for complete
validation [12,56,59,60,268]. Gender speciﬁc mRNA and miRNA
gene expression patterns to internal 239Pu exposure have been
deciphered in former Mayak workers [269,270], which are
promising markers of internal alpha-particle exposure and
warrant further validation.
3.8.3. New biomarkers of effects
Compared to biomarkers of low LET IR, biomarkers of effects of
internal emitters are more likely to be speciﬁc to the “target tissues
or organs” of each radionuclide. To date potential biomarkers of
IR-induced thyroid disease identiﬁed are those associated with
131I exposure [131,271].
131I associated gene expressions in thyroid tumours have been
investigated, however, no common alterations were found
(summarised in Supplementary Table 3.8.3 and references there
in). Major limitations of these transcriptomic studies might be the
small sample sizes. Another approach for the elucidation of
131I speciﬁc molecular ﬁngerprints was an integrative data analysis
combining genomic copy number data with mRNA and protein
expression levels. Using such an approach on PTC from young
thyroid cancer patients exposed to 131I from the Chernobyl fall-out,
an apparent IR-speciﬁc DNA copy number gain on chromosomal
band 7q11 and over-expression of CLIP2 mRNA and protein were
found [131,271]. A 131I dose-response relationship for the CLIP2 IR
marker in two Ukrainian PTC cohorts for young patients with age at
operation less than 20 years and age at exposure less than 5 years
has highlighted the potential importance of this biomarker in low-
dose radiation research [272]; no dose-response has been seen,
however, in a separate cohort in Belarus (Grellier et al., in
preparation).
Because of the chemical toxicity of certain radionuclides (e.g.:
U, Be, Np, Ag, Pb, Tc, Se, B, Cd) biomarkers of toxic effects which are
poorly covered by most epidemiological databases (e.g., kidney or
brain toxicity) [273,274] can be of interest to discriminate between
chemical and radiological effects. For instance, given that the
kidney is the most susceptible human organ to the chemical
toxicity of U, the use of speciﬁc and sensitive biomarkers ofFig. 2. Roadmap for Developing Biomarkers of Radiation Exnephrotoxity such as Kim-1, b2-microglobuline, tubular enzymes
or osteopontin [275–277] are promising.
Biomarkers of adverse biological effects have been investigated
in several animal models. For instance speciﬁc cardiovascular
markers associated with cardiovascular effects resulting from 137Cs
exposure [278,279] and kidney and brain markers after uranium
exposure (total calculated dose of 0.15 mGy on the kidney) have
been identiﬁed [280–283]. Biomarkers of adaptive response were
observed in certain conditions of chronic exposure of mice to 137Cs
(absorbed dose 5–150 mGy) where inﬂammatory cytokines
decrease [279] or chronic exposure of rats to uranium where
renal glutathione levels increase dose-dependently (absorbed dose
to the kidney 0.15 mGy to 5mGy) [284].
4. Discussion
4.1. Past and future
Pernot et al. [9] reviewed biomarkers for low dose IR
epidemiological studies, and deﬁned different classes (exposure,
susceptibility, late effects, and persistent effects). The review
raised awareness of the criteria required for a biomarker to be
useful and helped focus research on the approaches and
technologies needed to promote the discovery and validation of
suitable biomarkers. It facilitated interactions between basic
scientists studying the responses to IR exposure, those engaged
in biomarker discovery and epidemiologists. The review also
exposed the limitations inherent to using biomarkers including the
need for sufﬁcient sensitivity and speciﬁcity, and practicality for
use in large scale studies using biological samples that can be
collected in a logistically and ethically acceptable way.
Gaining a mechanistic understanding of the biochemical
processes induced by low doses of IR is an important complement
to the molecular epidemiological estimates of risk of low dose IR
exposure as originally discussed in the HLEG report [285], and
more recently the HPA’s independent Advisory Group on ionizing
radiation report on Human Radiosensitivity [286] and the NCRP
scientiﬁc commentary on Health Effects of low doses of radiation:
perspectives on integrating radiation bioogy and epidemiologyposure, Susceptibility, Late Effects or Persistent Effects.
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induced biomarker projects” and the rapid development of
bioinformatics/system biology should provide the tools to identify
the mechanisms underlying the cellular processes induced in
response to low dose IR. Understanding the nature of the primary
cellular targets, which are broader than just DNA, may help to
evaluate the long-term impact on transformation, senescence or
other endpoints relevant for the onset of health effects and would
also identify novel targets for approaches for amelioration or
protection from long-term health effects. Along with the relevance
for IR protection research, a basic understanding of the mecha-
nisms of action of low dose IR and their possible impact on human
health could be important for low dose risk estimates from other
stressors/pollutants in our envirnonment.
Since the Pernot et al. publication [9], there has been progress in
the identiﬁcation of potential new biomarkers of exposure and late
effects related to advances in metabolomics and transcriptomics.
The robust ﬁndings from in vitro and in vivo animal models using
much lower doses than previously used (below 1 Gy) highlight
these advances. The increasing number of potential new biomark-
ers underpins the need to establish guidelines for the processes
underlying biomarker validation, and a key aspect of this updated
review is the development of a roadmap (Fig. 2). It is crucial that
informed and carefully evaluated decisions are made on when to
progress or drop a biomarker with issues of reproducibility,
sensitivity and speciﬁcity being critical to the decision. Based on
this roadmap the development status of proposed biomarkers for
IR epidemiological studies have been reviewed (Table 3). One
biomarker that has moved to the ﬁnal stages of development is IR
speciﬁc mRNA transcript proﬁles. However, most potential
biomarkers have not reached these stages and for some there isTable 3
Development status of radiation biomarkers.
Field Endpoint BM of low d
Cytogenetics
Improved quantiﬁcation of CBMN assay GO-applicat
Chromosome aberrations analysis using PCC + ﬁsh GO-applicat
RET/PTC1 and RET/PTC3 rearrangements in PTC STOP not ra
EVT6/NTRK3 rearrangements in PTC 
Analysis of Micronucleated reticulocytes (mouse studies to date) GO- develop
DNA/nucleotide pool lesions
gH2AX STOP
interlab vari
extracellular 8 oxoG NO 
CtDNA GO-validatio
Germline variants/radiation induced mutations
Multigene signatures GO-discover
Radiation speciﬁc mutation proﬁle GO-discover
Gene ampliﬁcation, transcriptional and expression proﬁling
Multigene signatures GO-develop
FDXR GO-validatio
CLIP2 ampliﬁcation and protein expression GO-validatio
DDR activation 
Novel and/or emerging ideas
Redox balance GO-discover
Metabolite biomarkers in urine, serum or saliva GO-discover
Radiation induced post-translational modiﬁcations GO-discover
Radiation speciﬁc DNA lesions GO-discover
Telomere length NO 
miRNAs GO-discover
LnRNAs eg PAPPA-AS1 and PARTICLE GO-discover
DRC assays GO-develop
Accumulation of common deletion in mitochrondria GO-discoversufﬁcient evidence that further development for use in the low
dose IR exposure ﬁeld is not warranted.
4.2. Can biomarkers in molecular epidemiological studies provide
insight into the outstanding questions relating to low dose exposures;
strengths and limitations?
A goal of current research in the low dose IR ﬁeld is to deﬁne the
shape of the dose response for induced health effects. The
integration of biomarkers into molecular epidemiology studies
remains in its infancy but has the potential to address this goal.
Possible strategies for addressing this for cardiovascular diseases
[10], and the effects of uranium exposure [287] were recently
reviewed by the DOREMI consortium.
These strategies cover not only the collection and timing of
appropriate biological samples but also issues common to all
epidemiological studies, such as study size, statistical power,
potential biases (such as confounding, selection and recall) and
random error. Typical confounders and potential effect modiﬁers
include age, gender, ethnicity, smoking status, other environmen-
tal, occupational or medical exposures, and iodine deﬁciency (for
IR induced thyroid cancer). If adequate control for confounding
factors is not possible, even the best powered molecular
epidemiological study may lead to incorrect inferences. Therefore,
efforts to collect good quality data on potential confounders in
molecular epidemiological studies are critical and are major
components in the proposed future studies to investigate
cardiovascular effects and uranium exposure [10,288,289]. Uncer-
tainties and bias in estimating IR dose and inaccuracies in outcome
determination will also affect study ﬁndings.
To date, and since the publication of the Pernot et al. review [9],
molecular epidemiological studies of low dose IR continue to beose exposure BM of response
Early effects Late effects
ion GO-application GO-application
ion GO-application GO-application
diation speciﬁc STOP not radiation speciﬁc STOP not radiation speciﬁc
GO-qualiﬁcation GO-qualiﬁcation
ment GO- development GO- development
ability-poor dosimetry
GO-validation
GO-qualiﬁcation GO-qualiﬁcation
n GO-validation GO-validation
y GO-discovery GO-discovery
y GO-discovery GO-discovery
ment GO-development GO-development
n GO-validation GO-validation
n GO-validation GO-validation
GO-discovery NO
y GO-discovery GO-discovery
y GO-discovery GO-discovery
y GO-discovery NO
y NO NO
GO-development GO-development
y GO-discovery GO-discovery
y GO-discovery GO-discovery
ment GO-development GO-development
y GO-discovery GO-discovery
Cytogenec biomarkers (dicentrics/chromosome abe rra ons)
Chromo som al rearrangements
Micronu cleated reculocytes
Radiaon indu ced DNA  lesions
gamm aH2AX
Circu la ng DNAs
Radiaon indu ced muta on proﬁle
Changes  in RNA proﬁles
Radiaon indu ced alternav e sp licing
Changes  in protein proﬁles
Radiaon indu ced protein post -translaonal 
modiﬁca ons
miR NA and non-coding RNAs e xpressi on proﬁles
Epigenec markers
RedOx imbal ance
Metabolom ics
Biophysica l markers
Mit ochondri al  biomarkers (oxi da on/ph osph oryl aon)
Mit ochondri al biomarkers (c omm on dele ons)
Biomarkers of inter nal exposure  (r adio -isotopes)
Detec table
Potenally  detec table
Not rep orted 
Exposure
Fig. 3. Biomarker detectability with time.
This heatmap representation allows the selection of an appropriate biomarker with
respect to time after exposure. Biomarkers were classiﬁed as easily detectable or
potentially detectable with modern technology and assuming the availability of
appropriate biological samples. It has to be noted that the majority of these
biomarkers have yet to be validated using the proposed roadmap as a biomarker of
low dose radiation exposure in human studies.
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studies is recognised but hampered by the logistics and costs of
obtaining and biobanking several thousand samples from appro-
priate cohorts. Biological samples were collected from only a small
proportion of the many large epidemiological studies of low dose
IR so far conducted – often only at a single time point and from a
small proportion of individuals. Also, if the association between
the biomarker and endpoint is weak, then the additional
information that it provides will be limited and not cost-effective.
One over-arching consideration that impacts on study design
and the potential for the collection of biological samples and thus
limits the choice of biomarkers is the issue of time since exposure.
Prospective studies have the potential to be highly informative and
to provide distinct information in comparison with retrospective
studies: biological samples and dosimetric information can be
collected before the onset of disease and longitudinal sample
collection and measurements may be possible. However, decades
are needed in order to obtain results on long term effects.
Retrospective studies are quicker but most of the biomarkers of
exposure reviewed here currently lack sensitivity, speciﬁcity and
persistence for use decades after exposure as illustrated in Fig. 3.
Retrospective studies may be suitable, however, for the assessment
of individual susceptibility and persistent effects, and for these a
case-control study design would reduce the number of samples
required. As discussed in Pernot et al. [9], bioassays can be
particularly useful in this setting to assess biomarkers of
susceptibility. It is recognised, however, that certain gene and
protein expression proﬁles could vary with age that can complicate
the interpretation of data.
Thus, whilst the use of biomarkers in molecular epidemiologi-
cal studies has the potential to provide mechanistic insight andincrease the power of studies to answer key radiation protection
questions, the choice of the most appropriate biomarkers in
different study designs needs to be carefully evaluated.
5. Conclusions
Biomarkers for IR epidemiology studies must be sensitive to and
speciﬁc for IR exposure, and need to be applicable to large numbers
of biological samples that can be conveniently and ethically
collected. These requirements continue to limit the number of
candidates that are suitable for assessing low dose IR exposure,
susceptibility, or effects. Technological and analytical develop-
ments and cost reductions are advancing the development of
potential biomarkers but challenges remain. Whilst innovative
ideas and increased mechanistic understanding of the responses to
low dose and LDR IR are aiding biomarker discovery, a key issue is
the decision of which biomarkers to progress. As seen in this
review, most potential biomarkers remain at the discovery stage.
For some, however, there is now sufﬁcient evidence that further
development is not warranted. Only one biomarker was identiﬁed
in the ﬁnal stages of development and as a priority for further
research, radiation speciﬁc mRNA transcript proﬁles.
Robust validation is essential and a roadmap is provided to
facilitate the progression from biomarker discovery to implemen-
tation. Use and periodic updating of this roadmap should allow the
most informative biomarkers to be incorporated into IR epidemi-
ology studies.
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